By Krish Krishnan, Chief Executive Officer and Suma Krishnan, Chief Operating Officer
Dear members of the EB Community,
As Rare Disease Day approaches, we are thrilled to introduce you to Krystal Biotech. People living with rare diseases are at the center of everything we do -- Krystal has an important mission of making a meaningful difference in the lives of patients with rare genetic conditions that do not have viable treatments. Krystal was founded with the innovative idea of using non-invasive gene replacement therapy to address the underlying cause of Dystrophic Epidermolysis Bullosa. And we get closer and closer to that goal every day.
B-VEC, our non-invasive gene replacement therapy candidate for DEB, has completed Phase 1 and Phase 2 clinical studies in 2019 at Stanford University. Promising results were seen and as a result we are further evaluating B-VEC to treat both RDEB and DDEB in a Phase 3 trial. We want to thank the patients, caregivers, and investigators who are participating in our clinical studies.
We believe working with advocacy groups, like debra of America, and incorporating feedback from patients and caregivers are crucial to developing our treatments. You are living with EB daily and know exactly what the needs are. We learn so much from this community and those insights fuel our passion.
At Krystal, our team’s collective empathy and clarity in purpose motivate us each and every day. Krystal was named after this clarity – a simple realization that we can do better. We are fortunate to have an exceptionally dedicated team here at Krystal whose drive to bring innovative therapies to patients is unrelenting.
While we have grown and our gene therapy platform is being explored to potentially treat other diseases, EB patients and their families and the entire EB community will always be very special to us. We hope you will join the Krystal Biotech group on EB Connect, where we can provide you with education, updates on our DEB clinical trial program, and information on other initiatives.
Krystal Biotech is a Platinum Sponsor of the 2020 Virtual debra Care Conference (DCC). debra of America is grateful for their support and commitment to the EB Community. Thank you, Krystal Biotech!
Click here to watch Krystal Biotech’s on-demand webinar, “Topical Gene Therapy - A New Direction in the Management of Dystrophic Epidermolysis Bullosa (DEB)”. You can also join the Krystal Biotech Group on EBconnect.org to chat directly with the team, receive updates on their Phase 3 clinical trial, and more.